Monte Rosa Therapeutics Inc (GLUE) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.39x

Monte Rosa Therapeutics Inc (GLUE) has a Cash Flow Reinvestment Rate of 0.39x as of September 2025, reinvesting $38.79 Million (capex $651.00K plus investments $38.14 Million) from operating cash flow of $100.43 Million. See GLUE cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.39x
(Capex + Investments) / Operating CF

Total Reinvested

$38.79 Million
Capex + Investments

Operating Cash Flow

$100.43 Million
USD

Capital Expenditures

$651.00K
USD

Monte Rosa Therapeutics Inc Cash Flow Reinvestment Rate (2024–2024)

Historical reinvestment intensity for Monte Rosa Therapeutics Inc across 1 annual periods. For the full cash flow conversion analysis, see GLUE cash flow metrics.

Annual Cash Flow Reinvestment Rate for Monte Rosa Therapeutics Inc (2024–2024)

Year-by-year capital reinvestment analysis for Monte Rosa Therapeutics Inc. See GLUE financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 1.15x $48.44 Million $42.00 Million $3.99 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow